Skip to main content
LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD. logo

LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 688739 ISIN · CNE100004ZP2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 480 across all filing types
Latest filing 2026-05-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688739

About LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD.

https://en.cdbio.cn/

Liaoning Chengda Biotechnology Co., Ltd. specializes in the research, development, manufacturing, and commercialization of human vaccines. The company is a global leader in the production of purified human rabies vaccines using large-scale Vero cell bioreactor technology. Its product portfolio includes inactivated Japanese encephalitis vaccines and various pipeline candidates targeting infectious diseases. Utilizing advanced cell culture platforms, the company maintains high-volume production capabilities while adhering to international quality standards. Its products are distributed extensively across domestic markets and exported to numerous countries worldwide. The organization focuses on technological innovation in biopharmaceuticals to address public health needs through the provision of safe and effective immunization solutions.

Recent filings

Filing Released Lang Actions
辽宁成大生物股份有限公司关于与控股股东及其全资子公司共同对外投资暨关联交易事项的进展公告
Capital/Financing Update Classification · 85% confidence The document is an official announcement on the Shanghai Stock Exchange by Liaoning Chenda Bio Co., Ltd. describing the progress of a joint external investment and related‐party transaction (including amounts, registration status, and funding details). It is not a full financial report or call transcript but an update on a financing/investment transaction and capital structure change. This fits the definition of a Capital/Financing Update (CAP).
2026-05-18 Chinese
辽宁成大生物股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is the official announcement of the resolutions and vote results from the 2025 Annual General Meeting of Liaoning Chengda Bio Co., Ltd. It details meeting attendance, individual resolution names, voting tallies, and outcomes. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-12 Chinese
辽宁成大生物股份有限公司关于购买董事、高级管理人员责任保险的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the company's decision to purchase Directors and Officers (D&O) liability insurance. It details the insurance coverage, premium, and authorization procedures, and mentions the board and shareholder meeting approvals required. There are no financial statements, earnings data, or detailed management discussion. The document is a formal announcement about a governance-related insurance matter affecting directors and senior management, not a report or financial filing. It fits best under Board/Management Information (MANG) as it concerns board and senior management risk management and governance matters.
2026-04-20 Chinese
辽宁成大生物股份有限公司2025年度董事会审计委员会履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2025年度董事会审计委员会履职报告" which translates to the "2025 Annual Board Audit Committee Performance Report." It details the audit committee's activities, meetings, supervision of external auditors, review of financial reports, internal control evaluations, and overall audit committee performance for the year 2025. The content focuses on audit committee duties and oversight rather than presenting full financial statements or a complete annual report. It is a specialized report related to audit committee work and audit supervision, not the full annual report or standalone audit opinion. This fits the category of an Audit Report / Information (AR), which includes audit committee reports and audit-related disclosures separate from the full annual report. The document length is under 5,000 characters but contains substantive content, so it is not merely an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2025
2026-04-20 Chinese
辽宁成大生物股份有限公司2025年年度报告摘要
Annual Report Classification · 100% confidence The document is titled "辽宁成大生物股份有限公司2025年年度报告摘要" which translates to "Liaoning Chengda Bio Co., Ltd. 2025 Annual Report Summary." It contains detailed information about the company's business, industry analysis, financial performance, risk factors, management discussion, and future outlook. The text includes financial figures such as net profit, dividend distribution plans, and audit opinions. It also discusses the company's products, market position, industry trends, and regulatory environment. The length of the document is substantial (15,000 characters), and it is clearly a summary of the full annual report, providing comprehensive financial and operational data for the fiscal year 2025. This matches the definition of an Annual Report (10-K) which covers company activity and full financial performance for the year. Therefore, the document should be classified as an Annual Report (10-K). FY 2025
2026-04-20 Chinese
辽宁成大生物股份有限公司2025年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising (募集资金) for the year 2025, including the amount raised, usage, management, and changes in investment projects. It references regulatory rules related to fundraising supervision and includes tables of funds raised, used, and remaining. It also contains auditor and sponsor institution opinions on the fundraising usage. The document is titled as a "专项报告" (special report) on fundraising funds storage and usage for the year 2025. It is not an annual report, earnings release, or management discussion but a specialized report on fundraising usage and compliance. This matches the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and detailed, not a brief announcement or certification, so it is not RPA or RNS. Therefore, the best classification is CAP with high confidence.
2026-04-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.